Literature DB >> 25305804

Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patients.

Katharina Heß1, Christine Böger1, Hans-Michael Behrens1, Christoph Röcken2.   

Abstract

The aim of this study was to investigate the expression of a panel of integrins in prostate cancer in order to explore their potential for tumor biology. Formalin-fixed and paraffin-embedded tissue samples of 1284 prostate cancer patients were retrieved from the archive of the Department of Pathology. Immunostaining was done with rabbit monoclonal antibodies directed against αvβ3, αvβ5, αvβ6, αvβ8, β3, and αv-pan. Staining results were correlated with clinicopathologic patient characteristics and patient survival. Immunostaining of tumor cells performed on whole tissue sections of 52 patients was sparse for αvβ3, αvβ6, and αvβ8, and more prevalent for αvβ5 and αv-pan. αvβ5, αvβ8, and αv-pan were selected for further analyses in tissue microarrays representing the entire study cohort. αvβ8 staining was generally observed in peripheral nerves. αvβ5 and αv-pan provided strong evidence for the differential expression of these integrins in prostate cancer. The expression was variable with regard to the histoanatomical/cytoanatomical localization, cell type, intensity of immunolabeling, and Gleason pattern. αvβ5 and αv-pan are differentially expressed in prostate cancer, and the differentiation of prostate cancer seems to influence integrin expression and subcellular distribution.
Copyright © 2014 The Author. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Gleason score; Immunohistochemistry; Integrins; Prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 25305804     DOI: 10.1016/j.anndiagpath.2014.09.001

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  12 in total

1.  Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression.

Authors:  Yuan Jiang; Jinlu Dai; Zhi Yao; Greg Shelley; Evan T Keller
Journal:  Mol Cancer Res       Date:  2017-03-17       Impact factor: 5.852

2.  Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer.

Authors:  Huimin Lu; Nicholas Bowler; Larry A Harshyne; D Craig Hooper; Shiv Ram Krishn; Senem Kurtoglu; Carmine Fedele; Qin Liu; Hsin-Yao Tang; Andrew V Kossenkov; William K Kelly; Kerith Wang; Rhonda B Kean; Paul H Weinreb; Lei Yu; Anindita Dutta; Paolo Fortina; Adam Ertel; Maria Stanczak; Flemming Forsberg; Dmitry I Gabrilovich; David W Speicher; Dario C Altieri; Lucia R Languino
Journal:  Matrix Biol       Date:  2018-03-09       Impact factor: 11.583

3.  Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.

Authors:  Mehdi Azizi; Hassan Dianat-Moghadam; Roya Salehi; Masoud Farshbaf; Disha Iyengar; Samaresh Sau; Arun K Iyer; Hadi Valizadeh; Mohammad Mehrmohammadi; Michael R Hamblin
Journal:  Adv Funct Mater       Date:  2020-03-03       Impact factor: 18.808

Review 4.  The functional role of integrins during intra- and extravasation within the metastatic cascade.

Authors:  Greta Sökeland; Udo Schumacher
Journal:  Mol Cancer       Date:  2019-01-18       Impact factor: 27.401

Review 5.  Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy.

Authors:  Ping-Hsiu Wu; Abayomi Emmanuel Opadele; Yasuhito Onodera; Jin-Min Nam
Journal:  Cancers (Basel)       Date:  2019-11-13       Impact factor: 6.639

6.  Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype.

Authors:  Brendan Connell; Pavel Kopach; Wenying Ren; Raghav Joshi; Stephen Naber; Ming Zhou; Paul Mathew
Journal:  Transl Androl Urol       Date:  2020-08

7.  Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection.

Authors:  Marina Y Zemskova; Maria V Marinets; Andrey V Sivkov; Julia V Pavlova; Andrey N Shibaev; Konstantin S Sorokin
Journal:  Front Oncol       Date:  2021-03-10       Impact factor: 6.244

8.  Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.

Authors:  Yue-Hong Shen; Fei Yang; Hua Wang; Zhi-Jian Cai; Yi-Peng Xu; An Zhao; Ying Su; Gu Zhang; Shao-Xing Zhu
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

Review 9.  Exploring the Role of RGD-Recognizing Integrins in Cancer.

Authors:  Markus Nieberler; Ute Reuning; Florian Reichart; Johannes Notni; Hans-Jürgen Wester; Markus Schwaiger; Michael Weinmüller; Andreas Räder; Katja Steiger; Horst Kessler
Journal:  Cancers (Basel)       Date:  2017-09-04       Impact factor: 6.639

10.  Therapeutic Potential of a Novel αvβ₃ Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type.

Authors:  Billy Samuel Hill; Annachiara Sarnella; Domenica Capasso; Daniela Comegna; Annarita Del Gatto; Matteo Gramanzini; Sandra Albanese; Michele Saviano; Laura Zaccaro; Antonella Zannetti
Journal:  Cancers (Basel)       Date:  2019-01-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.